retatrutide type 2 diabetes phase 2 results 2024 ada Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Phase 2 trial results demonstrate

These medications, which mimic the functions of the naturally occurring hormone GLP-1 (glucagon-like peptide-1), have been lauded for their efficacy in not only controlling blood sugar levels but also promoting weight loss

This unique triple-action mechanism is designed to support metabolic regulation, appetite control, and energy balance, making Retatrutide one of the most advanced peptide concepts in the wellness and metabolic category

The EMA performs a similar function for medicines approved across the European Union

That third pathway is the reason researchers believe retatrutide may exceed the results of currently available agents